Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Authors

Yusuke Naoi, Ryota Chijimatsu, Tomohiro Urata, Kazutaka Sunami, Toshi Imai, Yuichiro Nawa, Yasushi Hiramatsu, Kazuhiko Yamamoto, Soichiro Fujii, Isao Yoshida, Tomofumi Yano, Kazuhiro Ikeuchi, Hiroki Kobayashi, Hiroyuki Murakami, Hideki Ujiie, Katsuma Tani, Kaho Kondo, Hirofumi Inoue, Shuta Tomida, Akira Yamamoto, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Merrill Boyle, Aixiang Jiang, Pedro Farinha, Katsuyoshi Takata, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda, David W Scott, Daisuke Ennishi

Published in

Haematologica. Jun 25, 2026. Epub Jun 25, 2026.

Abstract

A CD79B-targeted antibody-drug conjugate, polatuzumab-vedotin has significantly improved outcomes in DLBCL, particularly in the activated B-cell-like (ABC) subtype. This indicates that CD79B expression varies among COO subtypes, although the expression level was not necessarily higher in ABC-DLBCL. Here, we evaluated CD79B protein expression by immunohistochemistry (IHC) in 590 de novo DLBCL cases, observing a CD79B gradient according to COO subtypes, with ABC-DLBCL showing the lowest expression, followed by GCB and dark-zone signature-positive (DZsigpos) cases in ascending order (P < 0.0001). This observation was fully validated in an independent population-based cohort of 272 cases derived from BC Cancer registry. Given that COO classification reflects the stages of normal germinal center (GC) B-cell differentiation, we further explored CD79B expression dynamics during B-cell maturation by performing single-cell proteomic and transcriptomic analyses. Analyses of 2,447 normal GC B-cells demonstrated a progressive decrease in CD79B expression as GC B-cells transitioned toward terminal differentiation. Collectively, our findings reveal a novel COO-dependent gradient of CD79B expression, particularly with lower expression in ABC-DLBCL.

PMID:
42345068
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.